

Phenotypic Heterogeneity of Circulating Tumor Cells in Lung Cancer Revealed by Immunocytochemical Profiling

Meryem AARAB*, Salma SAADI, Imane TABYAOU, Nadia TAHIRI JOUTI


Laboratory of Cellular, Molecular, Inflammatory, Degenerative and Oncologic Pathophysiology - Faculty of Medicine and Pharmacy of Casablanca, Hassan II University – Casablanca, Morocco

INTRODUCTION & AIM

Tumor heterogeneity is a major challenge in lung cancer, contributing to disease progression, metastatic dissemination, and therapeutic resistance [1]. Circulating tumor cells (CTCs) provide a minimally invasive opportunity to investigate this heterogeneity through liquid biopsy [2]. However, increasing evidence suggests that these cells extend beyond the classical epithelial CTC phenotype and may include transitional or hybrid populations that are not captured by epithelial marker-restricted approaches [3–5].


The present study aimed to characterize the phenotypic diversity of circulating tumor-associated cells in newly diagnosed lung cancer patients using a cytoBlock-based enrichment protocol previously described by our team [6], combined with immunocytochemical profiling targeting epithelial and hematopoietic markers.

METHOD



RESULTS & DISCUSSION

The study population consisted of 100 newly diagnosed lung cancer patients (mean age: 64 years), predominantly male (83%), with a high prevalence of smoking history (80%). Most patients presented with advanced disease, with 94% diagnosed at stages III–IV. Representative morphological and immunocytochemical findings are shown below.



Our observations are consistent with previous reports describing phenotypic plasticity among circulating tumor-derived cells. Gast et al. demonstrated the existence of CHCs expressing both tumor and leukocyte markers, while Dietz et al. reported that such hybrid populations may exceed classical CTCs in frequency [3,4]. Likewise, studies investigating epithelial–mesenchymal transition have shown that some CTCs may lose epithelial marker expression while retaining metastatic potential [5].

CONCLUSIONS

Using a cytoBlock-based approach combined with immunocytochemistry, we identified a broad spectrum of circulating tumor-associated cells in lung cancer patients. Three major phenotypic categories were observed: conventional epithelial CTCs, CHCs co-expressing epithelial and hematopoietic markers, and atypical marker-negative cells displaying malignant morphology.

The detection of CHCs (47%) and marker-negative atypical cells highlights the limitations of epithelial marker-restricted approaches and suggests that circulating tumor-associated cells encompass a broader phenotypic spectrum than conventional CTC definitions. We thus conclude that integrating morphological assessment with multiparametric immunocytochemical profiling provides a more comprehensive characterization of circulating tumor heterogeneity and may improve the biological relevance of liquid biopsy approaches in lung cancer.

REFERENCES

- [1] Hanahan D. Hallmarks of Cancer: New Dimensions. *Cancer Discovery*. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059.
- [2] Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. *Cancer Discovery*. 2021;11(4):858–873. doi:10.1158/2159-8290.CD-20-1311.
- [3] Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson KT, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shastri V, Iizuka S, Flynn P, Watson S, Korkola JE, Gray JW, Coussens LM, et al. Cell Fusion Potentiates Tumor Heterogeneity and Reveals Circulating Hybrid Cells that Correlate with Stage and Survival. *Science Advances*. 2018;4(9):eaat7828. doi:10.1126/sciadv.aat7828.
- [4] Dietz MS, Sutton TL, Walker BS, Gast CE. Hybrid Cells in Cancer: Implications for Disease Progression and Liquid Biopsy. *Cancers (Basel)*. 2021;13(19):4868. doi:10.3390/cancers13194868.
- [5] Pastushenko I, Blanpain C. EMT Transition States During Tumor Progression and Metastasis. *Nature Reviews Cancer*. 2019;19(11):605–620. doi:10.1038/s41568-019-0157-5.
- [6] Aarab M, Saadi S, Tabyaoui I, Badre L, Jouti N. An Improved Method for Paraffin-Embedded Cytological Preparations: Application to the Detection of Circulating Tumour Cells. *Contemporary Oncology (Pozn)*. 2023;27(1):35–40. doi:10.5114/wo.2023.127190.